Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAOR.L Regulatory News (AOR)

  • There is currently no data for AOR

AorTech Enters Orthopaedic Market

17 Jan 2011 07:00

RNS Number : 5556Z
Aortech International PLC
17 January 2011
 



For Immediate Release

17 January 2011

 

 

AorTech Enters Orthopaedic Market with Polymer Licence and

Manufacturing Deal

 

AorTech International plc (AIM: AOR) the biomaterials and medical device development company, has reached a non-exclusive licensing agreement with a leading multi-national orthopaedic firm for the first use of its Elast-Eon™ polymers in a next generation orthopaedic implant. The device is in late stage development and uses AorTech's proprietary Reaction Injection Moulding (RIM) technology. Clinical trials are anticipated to commence sometime in the 3rd quarter of 2011.

 

AorTech CEO Frank Maguire stated, "This co-development project is one of several we currently have underway with both large and early stage orthopaedic device firms. These programs encompass a spectrum of device design platforms including lumbar, cervical and thoracic spine, hip, knee and intramedullary nail devices. All of these co-development projects are leveraging both our best-in-class soft biostable polymer materials along with our proprietary small part RIM technology. The outstanding metal to polymer and polymer to polymer bonds we are achieving with the utilization of RIM are providing design options for implantable orthopaedic device teams that were previously not possible."

 

Typical of other AorTech agreements, this transaction includes licensing fees in the form of up front and milestone payments along with provisions for polymer and manufactured component sales.

 

 

 

-Ends-

 

 

For further information please contact:

 

AorTech International plc

Frank Maguire, Chief Executive

Tel: + 1 801 201 4336

 

Evolution SecuritiesBobbie Hilliam / Chris Clarke

Tel: +44 20 7071 4300

 

AorTech International plc

Sarah Price, Investor Relations

Tel: + 1 801 550 4349

e-mail sprice@aortech.com

About AorTech

 

AorTech develops and manufactures biostable, implantable polymers, including Elast-Eon™ and ECSil™, the world's leading long-term implantable co-polymers. With more than 3 million implants and over four years of successful clinical use, AorTech polymers are currently used in cardiology, orthopaedic, urological and gastroenterological applications, including pacing leads, cardiac cannulae and stents. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

 

Elast-Eon™ and ECSil's™ biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. Our polymers can be processed using solution casting, ERIM and conventional thermoplastic extrusion and molding techniques. AorTech provides a range of materials in a variety of application-specific formulations for use in medical devices and components.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBRMTTMBBBMRB
Date   Source Headline
17th Jun 20207:00 amRNSChange of Name and Rebranding
8th Jun 20207:00 amRNSUpdate on Elective Surgery and Customer Orders
27th May 20207:00 amRNSNew Patent
20th May 20207:00 amRNSGrant Funding for Subsidiary
13th May 20207:00 amRNSTrading Update
14th Apr 202010:27 amRNSFurther Update re COVID-19
2nd Apr 20202:13 pmRNSHolding(s) in Company
1st Apr 20201:36 pmRNSDirector/PDMR Shareholding
31st Mar 202010:28 amRNSResult of General Meeting and Total Voting Rights
30th Mar 20203:37 pmRNSUpdate re Acquisition of RUA and COVID-19
25th Mar 20207:00 amRNSUpdate re Acquisition and General Meeting
11th Mar 20207:00 amRNSProposed Acquisition of RUA Medical & Name Change
21st Jan 20207:00 amRNSExtension to Agreement with RUA Medical
6th Jan 20207:00 amRNSHeart Valve Development Update
2nd Dec 20197:00 amRNSNew Share Option Scheme and Grant of Share Options
29th Nov 20197:00 amRNSHalf-year Report
27th Nov 20191:09 pmRNSNew Licence Agreement
11th Oct 20197:00 amRNSTrading Update
3rd Sep 20191:14 pmRNSHolding(s) in Company
19th Aug 20192:53 pmRNSResult of AGM
5th Aug 20191:36 pmRNSPosting of Report & Accounts and Notice of Meeting
29th Jul 201912:52 pmRNSHolding(s) in Company
17th Jul 20197:00 amRNSFinal Results
8th Jul 201911:05 amRNSSecond Price Monitoring Extn
8th Jul 201911:00 amRNSPrice Monitoring Extension
19th Jun 20197:01 amRNSChange of Adviser
19th Jun 20197:00 amRNSDirectors' Disclosures
17th Jun 201910:47 amRNSDirectors' Disclosures
14th May 20197:00 amRNSTrading Update
24th Jan 201912:36 pmRNSCompany Update
22nd Nov 20187:00 amRNSInterim Results
15th Oct 20185:34 pmRNSHolding(s) in Company
5th Sep 20187:00 amRNSHolding(s) in Company
30th Aug 201811:18 amRNSHolding(s) in Company
23rd Aug 20182:03 pmRNSResult of AGM
23rd Aug 20187:00 amRNSAGM Statement
26th Jul 20183:33 pmRNSHolding(s) in Company
25th Jul 20184:40 pmRNSSecond Price Monitoring Extn
25th Jul 20184:35 pmRNSPrice Monitoring Extension
20th Jul 20187:00 amRNSFinal Results
4th Jul 20187:00 amRNSNew Patent Issued
28th Jun 20187:00 amRNSDevelopment and Supply Agreement with RUA Medical
26th Jun 201812:49 pmRNSNew Patent Issued
19th Jun 20189:30 amRNSDevelopment Agreement Signed
15th Jun 20183:54 pmRNSHolding(s) in Company
13th Jun 201811:47 amRNSHolding(s) in Company
8th Jun 201812:02 pmRNSResult of GM and TVR
8th Jun 20187:00 amRNSResult of Open Offer
22nd May 201812:00 pmRNSPosting of Circular
21st May 20187:00 amRNSConditional Placing and Proposed Open Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.